pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,840 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1853Endpoints1439Fierce Biotech754BioSpace744BioPharma Dive544raps249onclive165fda recalls
therapy area
allOncology12820Rare Disease3324Immunology2980Cardiology2845Hematology2281Pulmonology2229Vaccines
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda press · 13h agoApprovalPositive↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 15h agoApprovalPositive↗ source
← prev
page 1 of 74
next →
118
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1128
Endocrinology & Metabolism805
Pain789
Nephrology782
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 1d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA nomination hours before Senate vote
    The White House has reportedly withdrawn the nomination of Dr. Heidi Overton, who was slated to become the FDA’s next commissioner, just hours before the Senate HELP Committee was set to vote. Ove…
    Fierce Biotech · 12h agoRegulatoryNegative↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 16h agoCRLNegative↗ source
  • FDA unveils Global Reliance Disclosure Program to speed international drug approvals
    The FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…
    fda press · 12h agoRegulatoryPositive↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 17h agoDealPositive↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 19h agoPositive readoutPositive↗ source
  • Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolio
    Medtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…
    Fierce Biotech · 21h agoDealPositive↗ source
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 23h agoNegative↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 1d agoPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 1d agoCRLNegative↗ source
  • EU regulators and industry discuss streamlining combination product oversight at summit
    At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
    raps · 1d agoRegulatoryNeutral↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 20h agoDealPositive↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 1d agoRegulatoryNeutral↗ source
  • Larbi Inc. recalls three lots of Yellow Dock Root over possible Salmonella contamination
    Larbi Inc. announced a recall of three lots of its Herb To Body Yellow Dock Root 4-oz product because it may be contaminated with Salmonella. The product was sold nationwide from January to Novemb…
    fda recalls · 9h agoCRLNegative↗ source
  • FDA to call AI "super intelligence" in all official communications
    The FDA announced that it will replace the term "artificial intelligence" with "super intelligence" in its official materials. The change applies to all correspondence, public communications, webs…
    raps · 1d agoRegulatoryNeutral↗ source
  • Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 1d ago↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 1d agoDealPositive↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 1d agoPositive readoutPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 1d agoDealPositive↗ source
  • AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trial
    AriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
    Fierce Biotech · 1d agoPositive readoutNeutral↗ source